Documents | Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Lymphoma (follicular non-Hodgkin's) - rituximab: review decision - March 2011 information
Appendix A: decision paper presented to the Institute's Guidance Executive ^{PDF 84.25 KB} 08 March 2011
Lymphoma (follicular non-Hodgkin's) - rituximab: review proposal - January 2011 information
Appendix A: provisional matrix of stakeholders ^{MSWord 57.5 KB} 17 January 2011
Appendix B: proposal paper presented to NICE's Guidance Executive ^{PDF 113.51 KB} 17 January 2011

Follicular lymphoma - rituximab: final appraisal determination

Follicular lymphoma - rituximab: final appraisal determination information
Follicular lymphoma - rituximab: final appraisal determination ^{PDF 95.22 KB} 10 January 2008
Response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 57.49 KB} 10 January 2008
Consultee and commentator comments on the ACD
Joint comment from British Society for Haematology and the Royal College of Physicians/Royal College of Pathologists Intercollegiate Committee in Haematology ^{PDF 24.78 KB} 10 January 2008
Joint comment from NCRI Lymphoma Clinical Studies Group, Royal College of Physicians, the Royal College of Radiologists, the Joint Collegiate Council for Oncology and the Association of Cancer Physicians ^{PDF 48.59 KB} 10 January 2008
Roche ^{PDF 1.16 MB} 10 January 2008
Royal College of Nursing ^{PDF 22.2 KB} 10 January 2008
Royal College of Pathologists ^{PDF 109.86 KB} 10 January 2008
Welsh Assembly Government ^{PDF 63.48 KB} 10 January 2008
Hancock ^{PDF 12.98 KB} 10 January 2008

Follicular lymphoma - rituximab: Appraisal consultation

Follicular lymphoma - rituximab: Appraisal consultation
Follicular lymphoma - rituximab: appraisal consultation document information
Follicular lymphoma - rituximab: Evaluation report
Expert written personal statements
Hancock ^{PDF 80.83 KB} 05 October 2007
Hamblin ^{PDF 19.01 KB} 05 October 2007
Manufacturer submission
Roche response to clarification letter ^{PDF 7.31 MB} 05 October 2007
Clarification letter from NICE ^{PDF 1.73 MB} 05 October 2007
Roche Products Limited ^{PDF 1007.29 KB} 05 October 2007
Lymphoma Association ^{PDF 86.41 KB} 05 October 2007
EMEA documents
EMEA letter ^{PDF 919.61 KB} 05 October 2007
EMEA scientific discussion ^{PDF 1.53 MB} 05 October 2007
BCSH Guidelines ^{PDF 2.94 MB} 05 October 2007
Evidence Review Group report
Supplemental Evidence Review Group report ^{PDF 121.19 KB} 05 October 2007
Lymphoma (follicular non-Hodgkin's) - rituximab: evidence review group report ^{PDF 654.13 KB} 05 October 2007
Pre-meeting briefing ^{PDF 153.59 KB} 05 October 2007

Response to consultee and commentators comments on the draft Matrix and Scope

Response to consultee and commentators comments on the draft Matrix and Scope ^{PDF 58.88 KB} 20 April 2007

Follicular lymphoma - rituximab: final scope

Follicular lymphoma - rituximab: final scope ^{PDF 37.18 KB} 12 April 2007

Letter to consultees and commentators

Letter to consultees and commentators ^{MSWord 29.5 KB} 26 January 2007